Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Wellbeing Digital Sciences Inc (OP: KONEF )

N/A UNCHANGED
Last Price Updated: 3:57 PM EST, Mar 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Wellbeing Digital Sciences Inc

< Previous 1 2 3 Next >
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and... 
Via Benzinga
Wellbeing Subsidiary KGK Science Announces Successful Results of UP446, a Nutraceutical Ingredient, in Positive Immune Defense Response
From Wellbeing Digital Sciences Inc.
Via Business Wire
Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial
Psychedelics biotechs Nova Mentis Life Science Corp. (OTCQB: NMLSF) and Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Sciences Inc. 
Via Benzinga
Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Subsidiary Mindscape Treats its 1,000th Patient
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Digital Announces the Appointment of Mohammad Sharifi to Board of Directors
From Wellbeing Digital Sciences Inc.
Via Business Wire
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy 
Via Benzinga
Wellbeing Digital Announces Resignation of Directors
From Wellbeing Digital Sciences Inc.
Via Business Wire
Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial
Psychedelics company Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Science Inc. has entered into a research services agreement with Canadian-based biotech Nova Mentis Life Science... 
Via Benzinga
Wellbeing Subsidiary KGK Science Enters into Research Contract With Nova Mentis for Phase II A Clinical Trial
From Wellbeing Digital Sciences Inc.
Via Business Wire
Successful Study On Transdermal CBD & THC Delivery Presents Benefits For Treating Chronic Conditions
Wellbeing Digital Sciences Inc. (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company announced that its wholl 
Via Benzinga
Wellbeing Subsidiary KGK Science Announces Successful Delivery of CBD and THC Through the Skin of Healthy Volunteers
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Digital Subsidiary KGK to Participate in Microdose Wonderland Miami Conference
From Wellbeing Digital Sciences Inc.
Via Business Wire
Psyched: Top Psychedelics Execs., 50% Of Americans Support Medical Psychedelics, Cary Grant's LSD Therapy & More
15 Global Psychedelics Executives To Keep An Eye On In 2022 
Via Benzinga
Pathway Health To Acquire IRP Health From Wellbeing Digital Sciences
Wellbeing Digital Sciences Inc. 
Via Benzinga
Wellbeing Announces Definitive Agreement to Divest IRP Health
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Digital to Participate at this Years’ Wonderland Miami Conference
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Digital Subsidiary KGK to Participate in the Supply Side West Conference
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Digital and Subsidiary KGK Science Applauds the Government of Alberta’s Move to Regulate the Use of Psychedelics
From Wellbeing Digital Sciences Inc.
Via Business Wire
Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
Alberta Becomes The First Canadian Province To Regulate Psychedelics-Assisted Therapy 
Via Benzinga
Wellbeing Subsidiary KGK Science Announces Psilocybin Microdose Capsule Formulation to be Submitted to Health Canada for Phase 2A Trial
From Wellbeing Digital Sciences Inc.
Via Business Wire
Ketamine Therapy At Your Doorstep, Growing Number Of Clinics Offer This Treatment Option
Being the sole psychedelic legally available as medicine, ketamine-assisted therapy services are expanding at a rapid pace across the U.S.  
Via Benzinga
Wellbeing Digital to Participate in the Cantor Fitzgerald Symposium on Mental Health Clinics
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Digital Signs LOI Manage Additional Clinics
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Subsidiary KGK Science Opens New Clinical Research Center to Reimagine a Healthier Future
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Digital to Participate in the Microdose Psychedelic Capital Conference
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Digital Reports 4Q Finances, 'Three Key Pillars' Stay Strong
Wellbeing Digital Sciences Inc. (OTC: KONEF) filed its financial results for the quarter ended July 31, 2022 and provided some insight on their most recent businesses. Numbers for the selected period... 
Via Benzinga
Wellbeing Digital Reports Financial Results for the Fourth Fiscal Quarter
From Wellbeing Digital Sciences Inc.
Via Business Wire
World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business... 
Via Benzinga
Wellbeing’ CEO Joins Benzinga’s Psychedelic Advisory Board
From Wellbeing Digital Sciences Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.